Sugi Predict

Sugi Predict / Compounds / SCHEMBL1979476

SCHEMBL1979476

SCHEMBL1979476

C[C@H](N)c1cccc[n+]1[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ MAOA P21397 4/20 0.35
▸ SLC6A2 P23975 2/20 0.35
▸ TAAR1 Q96RJ0 2/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ SLC2A1 P11166 1/20 0.35
▸ RAB9A P51151 2/20 0.33
▸ MAOB P27338 1/20 0.32
▸ HDAC8 Q9BY41 1/20 0.32
▸ MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL996540 0.82 KMT2A (0.44) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL31119425 0.78 L3MBTL1 (0.42) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL11256258 0.78 KMT2A (0.42) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL11767521 0.78 L3MBTL1 (0.42) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL10116257 0.75 KMT2A (0.40) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL31119438 0.75 KMT2A (0.40) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL7412921 0.75 KMT2A (0.40) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL3674235 0.73 LMNA (0.43) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL3626864 0.73 LMNA (0.43) KMT2AL3MBTL1LMNAHTTKDM4E
SCHEMBL27820534 0.73 LMNA (0.43) KMT2AL3MBTL1LMNAHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144069-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2011-06-16 — — US disclosed
US-20110144069-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2011-06-16 — — US disclosed
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2009-04-23 — — US disclosed
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2009-04-23 — — US disclosed
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2008-08-28 — — US disclosed
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 KMT2A 3573/4885L3MBTL1 3222/4885LMNA 2353/4885
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 KMT2A 3573/4885L3MBTL1 3222/4885LMNA 2353/4885
US-20110144069-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 KMT2A 3573/4885L3MBTL1 3222/4885LMNA 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.